Attention Deficit Hyperactivity Disorder is one of the most common neuropsychiatric disorders diagnosed in children. It can often last into adulthood. For most, this will be treated with behavioral therapy and medications. This program discusses the benefits and harms of recommending stimulants, as well as possible behavioral interventions and usage of non-stimulant drugs. The session will provide pharmacists with a comprehensive overview of the latest guideline recommendations for the treatment of ADHD which pharmacists can utilize in practice.
At the completion of this activity, the participant should be able to:
- Identify the symptoms and behaviors characteristic of Attention Deficit Hyperactivity Disorder (ADHD)
- Explain the role of non-pharmacologic treatments for ADHD
- Compare the dosing, efficacy, safety, monitoring, and dosage forms of pharmacotherapy used to treat ADHD
- Evaluate the advantages and disadvantages of stimulant and non-stimulant medications with regard to effectiveness and abuse potential
Alexis Bogannam, B.S, PharmD, is a graduate of Northeastern University, class of 2023. She is currently completing her PGY-1 pharmacy clinical practice residency with Massachusetts College and Pharmacy and Health Sciences/Atrius Health, focusing on ambulatory care. She also holds an adjunct pharmacy faculty position at MCPHS, facilitating various courses including Pharmacotherapeutics Seminar, and Advanced Practice Management lab.
Registration Fee: Free for MCPHS alumni, full-time staff, and for all other professionals.
Release Date: March 31, 2023
Expiration Date: March 31, 2024
ACPE UAN: 0026-0000-23-008-H01-P Knowledge
Topic Designator: Drug Therapy
Contact Hours: 1 (0.1 CEU)
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Massachusetts College of Pharmacy and Health Sciences designates this activity for a total of 1 contact hour (0.1 CEUs).
In order to receive credit, the participant must view the entire presentation and complete the pre and post-tests, and evaluation form. Upon completion, participant credit will be reported to CPE Monitor. Transcripts may be printed from CPE Monitor.
Massachusetts College of Pharmacy and Health Sciences adheres to the ACPE Standards for Integrity and Independence in Continuing Education. It is the policy of MCPHS that the speakers and planning committee members disclose all financial relationships with ineligible companies within the last 24 months, and that relevant conflicts of interest are mitigated. Speakers will disclose any off-label/unapproved use of drugs or devices during their presentation.
Dimple Gandhi, PharmD, RPh, is an MCPHS post-doctoral Biopharmaceutical Fellow at Takeda Pharmaceuticals, an ineligible company. The content of this presentation does not relate to the product lines or solutions produced or offered by Takeda Pharmaceuticals.
Content Reviewer, Paul Belliveau, PharmD, holds no financial relationships with ineligible companies.
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies, related to the content of this presentation.
No funding from industry provided for this event. No exhibitors will be present.